Long the fixation of physicists worldwide, a tiny particle is found

After decades of intensive effort by both experimental and theoretical physicists worldwide, a tiny particle with no charge, a very low mass and a lifetime much shorter than a nanosecond, dubbed the “axion,” has now been detected by the University at Buffalo physicist who first suggested its existence in a little-read paper as early as 1974.

Got cotton? Texas researchers’ discovery could yield protein to feed millions

Researchers at the Texas Agricultural Experiment Station used RNAi to reduce the toxic compound gossypol from cottonseed to a level that is considered safe for consumption, but left the compound in the rest of the plant to ward off insects and disease. Once commercialized, seed from these plants could provide a new, high-protein food available to 500 million people a year.

Brain :: Speak, memory – Research challenges theory of memory storage

During sleep, freshly minted memories move from the hippocampus, part of the “old” brain, to the neocortex, or “new” brain, for long-term storage. This has been the reigning theory for decades. Brown University research provides the strongest proof yet of this interaction between the old and new brains — and offers surprising evidence that challenges critical details of this theory of learning and memory. Results appear in Nature Neuroscience.

Depression :: Carefully monitored treatment can help two-thirds of those who suffer from depression

More than two-thirds of people who suffer from major depression can become symptom-free if they are willing to work with their doctors and try various treatments to determine which work best for them, which may involve taking different antidepressants or adding cognitive therapy to the mix.

Breast Cancer :: Breast cancer gene offers promising target for drugs

Researchers at UT Southwestern Medical Center have for the first time described how multiple copies of a gene are responsible for metastases in early-stage breast cancer and poor prognosis for patients. In a study published in this week’s issue of the Proceedings of the National Academy of Sciences, the gene, called uPAR, offers a promising target for therapeutic drugs to stop or slow the progression of the disease and could serve as a screening tool for assessing which types of drugs a patient will respond to.